Table 2. Clinical characteristics, prior antibiotic usage, and underlying conditions in 119 patients colonized or infected with carbapenem-resistant MDR-GNB.
| characteristic | n (%) |
|---|---|
| preceding ICU stay within 6 months prior to detection of MDR-GNB | 68 (57.1%) |
| first isolation of carbapenem-resistant MDR-GNB during ICU stay1 | 36 (30.3%) |
| ≥ 3 hospital admissions within 6 months prior to detection of MDR-GNB | 40 (33.6%) |
| preceding stay in long term care facilities | 14 (11.8%) |
| antimicrobial therapy within 6 months prior to detection of MDR-GNB | 105 (88.2%) |
| ureido-penicillins2 | 36 (30.3%) |
| cephalosporins, 3rd generation2 | 43 (36.1%) |
| carbapenems2 | 74 (62.2%) |
| fluoroquinolones2 | 36 (30.3%) |
| malignant disease | 45 (37.8%) |
| hematologic malignancy | 25 (21.0%) |
| solid tumor | 23 (19.3%) |
| immunosuppressive drugs | 32 (26.9%) |
| diabetes mellitus | 27 (22.7%) |
| chronic kidney disease | 22 (18.5%) |
| stem cell transplantation | 16 (13.4%) |
| organ transplantation | 11 (9.2%) |
| liver transplantation | 5 (4.2%) |
| kidney transplantation | 4 (3.4%) |
| heart transplantation | 2 (1.7%) |
| congestive heart disease | 12 (10.1%) |
| chronic wounds | 12 (10.1%) |
| cystic fibrosis | 8 (6.7%) |
| long-term Foley urine catheter | 8 (6.7%) |
| liver cirrhosis | 7 (6.0%) |
| long-term tracheostoma | 6 (5.0%) |
| chronic obstructive pulmonary disease | 6 (5.0%) |
1Sample taken ≥ 48 hours after admission to ICU.
2Combination therapies were administered to several patients resulting in a cumulative percentage of > 100%.